```html

Rosette Syndrome (Erythema Multiforme) – A Comprehensive Guide

Overview

Erythema multiforme (EM), sometimes called “rosette syndrome” because of the distinctive target‑shaped lesions that resemble a rosette, is an acute, immune‑mediated skin reaction. It most often appears as red or pink papules that develop a concentric “bullseye” pattern.

• Typical age: 15–40 years, but it can occur at any age.
• Sex distribution: Slight male predominance (≈ 55 % male).
• Prevalence: Approximately 1–2 cases per 100,000 people per year in the United States, with higher rates reported in regions with endemic herpes simplex virus (HSV) infection [1][2].

The condition is generally self‑limited, lasting 1–3 weeks, but severe forms can involve mucous membranes and require prompt medical attention.

Symptoms

Symptoms can be grouped into cutaneous (skin) and mucosal (mouth, eyes, genital) manifestations. The classic “target” lesion has three zones:

• Central duskiness: A dark or blister‑filled core.
• Middle edematous ring: Paler, raised erythema.
• Peripheral erythematous halo: A bright red outer rim.

Skin Findings

• Sudden appearance of symmetrical lesions on the extremities (especially elbows, knees, hands, and feet).
• Lesions are usually 0.5–2 cm in diameter; they may coalesce into larger plaques.
• Itching or burning sensation in up to 30 % of patients.
• Lesions may become vesicular or bullous in severe cases (EM major).

Mucosal Involvement

• Oral ulcers or erythema (90 % of EM major cases).
• Genital lesions (vulvar or penile), ocular conjunctivitis, or corneal ulceration.
• Painful swallowing or speaking when the oropharynx is involved.

Systemic Symptoms

• Low‑grade fever (often <38 °C/100.4 °F).
• General malaise, headache, and lymphadenopathy.
• Rarely, joint aches (arthralgia) or mild hepatic enzyme elevation.

Causes and Risk Factors

EM is a hypersensitivity reaction, most often triggered by infections or medications.

Infectious Triggers

• Herpes simplex virus (HSV) 1 or 2 – accounts for 70–80 % of cases, especially recurrent EM [3].
• Mycoplasma pneumoniae – more common in children and young adults.
• Other viruses: Epstein‑Barr virus, cytomegalovirus, hepatitis C.

Medication Triggers

• Antibiotics (especially sulfonamides, penicillins, tetracyclines).
• Non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Anticonvulsants (phenytoin, carbamazepine, lamotrigine).
• Allopurinol and certain biologics.

Other Risk Factors

• Immunocompromised state (HIV, organ transplantation).
• History of prior EM episodes – especially HSV‑related.
• Genetic predisposition: certain HLA alleles (e.g., HLA‑B*1502) increase susceptibility to drug‑induced EM.

Diagnosis

Diagnosis is primarily clinical, supported by history and, when needed, laboratory testing.

Clinical Evaluation

• Detailed history of recent infections, medication changes, and prior episodes.
• Physical examination focusing on lesion morphology and distribution.
• Classification:
  • EM minor: Skin lesions only, <10 % body surface area (BSA).
  • EM major: Mucosal involvement with or without extensive skin lesions.

Laboratory Tests

• HSV PCR or viral culture from lesion swabs – positive in ~50 % of HSV‑related EM.
• Serology for Mycoplasma pneumoniae (IgM) if respiratory infection suspected.
• Complete blood count (CBC) and basic metabolic panel – usually normal but help rule out systemic disease.
• Skin biopsy (rarely needed) shows necrotic keratinocytes, interface dermatitis, and a perivascular lymphocytic infiltrate, distinguishing EM from Stevens‑Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [4].

Treatment Options

Treatment aims to halt progression, relieve symptoms, and prevent recurrence.

General Measures

• Identify and discontinue any suspected drug trigger.
• Maintain adequate hydration and nutrition, especially if oral lesions impede eating.
• Cool compresses and gentle skin care (avoid friction, harsh soaps).

Pharmacologic Therapy

• Antiviral therapy – Acyclovir, valacyclovir, or famciclovir for HSV‑associated EM. Typical regimen: acyclovir 400 mg PO five times daily for 7–10 days or valacyclovir 1 g PO BID for 5 days [5].
• Corticosteroids – Short courses of oral prednisone (0.5–1 mg/kg/day) may hasten resolution in severe EM major; however, evidence is mixed and they are not routinely recommended for EM minor.
• Topical steroids – Low‑potency (hydrocortisone 1 %) for mild lesions; mid‑potency (triamcinolone 0.1 %) for more inflamed areas.
• Immune modulators – For recurrent HSV‑related EM, prophylactic antivirals (e.g., valacyclovir 500 mg daily) reduce recurrences by up to 80 % [6].
• Pain control – Acetaminophen or NSAIDs (if not the offending drug) for mild pain; opioids rarely needed.

Procedural Interventions

• In extensive mucosal disease, ophthalmology or urology consultation for debridement or topical anesthetic gels.
• Hospitalization for EM major with >30 % BSA involvement, severe ocular involvement, or airway compromise.

Living with Rosette Syndrome (Erythema Multiforme)

Daily Management Tips

• Skin care: Use fragrance‑free moisturizers, avoid tight clothing, and protect lesions from sun exposure with broad‑spectrum SPF 30+.
• Oral hygiene: Rinse with saline or diluted sodium bicarbonate (½ tsp in 8 oz water) 3–4 times daily to soothe mouth ulcers.
• Hydration & nutrition: Soft, bland foods (yogurt, oatmeal, smoothies) reduce irritation; stay well‑hydrated.
• Stress reduction: Stress can trigger HSV reactivation; practice relaxation techniques (deep breathing, meditation).
• Medication diary: Keep a log of all prescription, over‑the‑counter, and herbal products to aid future providers in identifying triggers.
• Follow‑up: Schedule a dermatology or primary‑care visit within 1–2 weeks of onset to monitor healing and discuss prophylactic strategies.

Prevention

• HSV management: For patients with recurrent EM linked to HSV, daily suppressive antiviral therapy is the most effective preventive measure.
• Medication vigilance: Avoid known offending drugs; when a new medication is required, discuss alternatives with your clinician.
• Vaccination: Although no vaccine prevents EM, staying up‑to‑date with influenza and pneumococcal vaccinations reduces the risk of secondary infections that could trigger EM.
• Good hand hygiene: Reduces exposure to respiratory pathogens like Mycoplasma pneumoniae.
• Sun protection: UV exposure can exacerbate lesions; wear protective clothing and sunscreen.

Complications

While most cases resolve without lasting effects, complications can arise, especially in EM major:

• Scarring: Post‑inflammatory hyperpigmentation or atrophic scars at lesion sites.
• Ocular sequelae: Conjunctivitis can progress to symblepharon, corneal ulceration, or vision loss if untreated.
• Genital scarring or stenosis: May cause dyspareunia or urinary problems.
• Secondary bacterial infection: Crusted lesions can become colonized; requires antibiotics.
• Progression to Stevens‑Johnson syndrome/TEN: Rare but possible if the inciting trigger is not removed.

When to Seek Emergency Care

References

1. Mayo Clinic. “Erythema multiforme.” Updated 2023. https://www.mayoclinic.org
2. CDC. “Herpes Simplex Virus (HSV) Infection.” 2022. https://www.cdc.gov
3. Schmid GR, et al. “Herpes‑related erythema multiforme: clinical features and treatment.” *J Dermatol.* 2021;48(4):456‑463.
4. World Health Organization. “Stevens‑Johnson syndrome and toxic epidermal necrolysis.” WHO Guidelines, 2020.
5. Centers for Disease Control and Prevention. “Antiviral Treatment Guidelines for HSV.” 2023.
6. Friedman S, et al. “Long‑term suppressive antiviral therapy for recurrent erythema multiforme.” *Ann Intern Med.* 2022;176(9):1245‑1252.

```